319 related articles for article (PubMed ID: 17459746)
21. Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors.
Wittayanarakul K; Hannongbua S; Feig M
J Comput Chem; 2008 Apr; 29(5):673-85. PubMed ID: 17849388
[TBL] [Abstract][Full Text] [Related]
22. Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes.
Lu Y; Yang CY; Wang S
J Am Chem Soc; 2006 Sep; 128(36):11830-9. PubMed ID: 16953623
[TBL] [Abstract][Full Text] [Related]
23. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Kaldor SW; Kalish VJ; Davies JF; Shetty BV; Fritz JE; Appelt K; Burgess JA; Campanale KM; Chirgadze NY; Clawson DK; Dressman BA; Hatch SD; Khalil DA; Kosa MB; Lubbehusen PP; Muesing MA; Patick AK; Reich SH; Su KS; Tatlock JH
J Med Chem; 1997 Nov; 40(24):3979-85. PubMed ID: 9397180
[TBL] [Abstract][Full Text] [Related]
24. Design of peptidomimetic inhibitors of aspartic protease of HIV-1 containing -Phe Psi Pro- core and displaying favourable ADME-related properties.
Frecer V; Berti F; Benedetti F; Miertus S
J Mol Graph Model; 2008 Oct; 27(3):376-87. PubMed ID: 18678515
[TBL] [Abstract][Full Text] [Related]
25. [Screening of new HIV inhibitors based on the database of traditional Chinese medicine].
Gao WN; Li Y; Zhang R; Gao H; Xu WR; Li AX; Du QS; Zhang X; Wei DQ
Yao Xue Xue Bao; 2006 Mar; 41(3):241-6. PubMed ID: 16758996
[TBL] [Abstract][Full Text] [Related]
26. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
27. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
[TBL] [Abstract][Full Text] [Related]
28. X-ray structure and conformational dynamics of the HIV-1 protease in complex with the inhibitor SDZ283-910: agreement of time-resolved spectroscopy and molecular dynamics simulations.
Ringhofer S; Kallen J; Dutzler R; Billich A; Visser AJ; Scholz D; Steinhauser O; Schreiber H; Auer M; Kungl AJ
J Mol Biol; 1999 Mar; 286(4):1147-59. PubMed ID: 10047488
[TBL] [Abstract][Full Text] [Related]
29. Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility.
Zoete V; Michielin O; Karplus M
J Mol Biol; 2002 Jan; 315(1):21-52. PubMed ID: 11771964
[TBL] [Abstract][Full Text] [Related]
30. Adaptive inhibitors of the HIV-1 protease.
Ohtaka H; Freire E
Prog Biophys Mol Biol; 2005 Jun; 88(2):193-208. PubMed ID: 15572155
[TBL] [Abstract][Full Text] [Related]
31. A peptide inhibitor of HIV-1 protease using alpha, beta- dehydro residues: a structure based computer model.
Siddiqui MI; Kataria S; Ahuja V; Rao GS
Indian J Biochem Biophys; 2001; 38(1-2):90-5. PubMed ID: 11563339
[TBL] [Abstract][Full Text] [Related]
32. Incorporating protein flexibility in structure-based drug discovery: using HIV-1 protease as a test case.
Meagher KL; Carlson HA
J Am Chem Soc; 2004 Oct; 126(41):13276-81. PubMed ID: 15479081
[TBL] [Abstract][Full Text] [Related]
33. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
Hou T; Yu R
J Med Chem; 2007 Mar; 50(6):1177-88. PubMed ID: 17300185
[TBL] [Abstract][Full Text] [Related]
34. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
Seibold SA; Cukier RI
Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
[TBL] [Abstract][Full Text] [Related]
35. Molecular dynamics simulations applied to the study of subtypes of HIV-1 protease common to Brazil, Africa, and Asia.
Batista PR; Wilter A; Durham EH; Pascutti PG
Cell Biochem Biophys; 2006; 44(3):395-404. PubMed ID: 16679526
[TBL] [Abstract][Full Text] [Related]
36. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
[TBL] [Abstract][Full Text] [Related]
37. Genotype dependent QSAR for HIV-1 protease inhibition.
Boutton CW; De Bondt HL; De Jonge MR
J Med Chem; 2005 Mar; 48(6):2115-20. PubMed ID: 15771454
[TBL] [Abstract][Full Text] [Related]
38. A combined QM/MM approach to protein--ligand interactions: polarization effects of the HIV-1 protease on selected high affinity inhibitors.
Hensen C; Hermann JC; Nam K; Ma S; Gao J; Höltje HD
J Med Chem; 2004 Dec; 47(27):6673-80. PubMed ID: 15615516
[TBL] [Abstract][Full Text] [Related]
39. Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes.
Rezácová P; Pokorná J; Brynda J; Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezác J; Grantz Sasková K; Sieglová I; Plesek J; Sícha V; Grüner B; Oberwinkler H; Sedlácek' J; Kräusslich HG; Hobza P; Král V; Konvalinka J
J Med Chem; 2009 Nov; 52(22):7132-41. PubMed ID: 19874035
[TBL] [Abstract][Full Text] [Related]
40. Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes.
Aruksakunwong O; Wolschann P; Hannongbua S; Sompornpisut P
J Chem Inf Model; 2006; 46(5):2085-92. PubMed ID: 16995739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]